Cancer immunology is study of understanding the role of immune system in the progression and development of cancer. The advanced and well known application is cancer immunotherapy, which utilizes the immune system as a treatment of cancer.
It is our pleasure to welcome you to “The Cancer Immunology & Tumor Immunology 2020” conference at Orlando on May 28-30-2020, hosted by Excel conferences. The scientific conference will cover a wide collection of topics with principle keynote presentations, Oral talks, Poster presentations, workshops, symposiums, and Exhibitions. The conference focus on major tracks as Tumor, Brain Tumor, cancer Biology, Tumor Immunotherapy- research, Paediatric-Oncology, Cancer Vaccines, Cancer Molecular biology, Cancer Biomarkers, Tumor Biology & drug targeting etc. The scientific program of the conference is broad and embraces different research aspects with focus on applied and advanced Tumor immunology, and in particular with a veterinary and medical interest. This spectrum meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges. Leading expert scientists and principle keynote speakers will present the latest and advanced achievements of multidisciplinary research dealing with drug action and resistance and highlight challenges that require a concerted multidisciplinary effort.
With members from around the world focused on learning about Tumor and Cancer immunology and its advances: this is your best opportunity to reach the largest assemblage of participants from Tumor & Cancer immunology community. conduct presentations, distribute information’s, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event, world-renowned speakers, the most recent technologies, developments, and the newest updates in The Cancer Immunology & Tumor Immunology 2020 are hallmarks of this conference.
The cancer immunotherapy market size range was valued at USD 58.1 Billion in 2018. Healthcare sector providers are focusing advanced research on improving cancer therapeutics and reduction in reformation rate of tumor post chemotherapy treatment.
The world cancer immunotherapy research market size range is likely expected to reach USD 126.9 billion by 2026. Increasing patient pool and higher mortality rate are augmenting the need for cancer immunotherapy. Furthermore, increasing number of approvals for new immunotherapeutic drugs is driving the world cancer immunotherapeutic market.
Rising Research and Development activities in the cancer immunotherapy field is resulting in introduction of advanced variants with enhanced efficacy and effectiveness of cancer treatment. Immuno-oncologics have shown promising results with improved survival and lower toxicity. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall cancer immunotherapy market.
Immunotherapies in the pipeline are likely to provide more treatment choices and better outcomes than existing therapies. Introduction of newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, designed to target receptors related to multiple myeloma, is poised to shape the future of the market. On-going studies on similar drugs intended to minimize adverse effects are projected to spur the growth of the market.
In addition, approval of PD-1 and CTLA-4 checkpoint inhibitors for melanoma and Non-Small Cell Lung Cancer (NSCLC) has been boosting the growth of the market. Approval of innovative immunotherapy drug forms, such as vaccines and adjuvants, is on a rise. Moreover, more immunotherapies are being tested for enhanced outputs, such as immune modulators and CAR T-cell therapy. These new approvals and on-going research are anticipated to stimulate the growth of the market over the forecast period.
By type, the global cancer immunotherapy market has been segmented into lung, breast, colorectal, melanoma, prostate, head & neck, ovarian, and pancreatic cancer. Majority of immunotherapy drugs and medicines including few mAb’s monoclonal antibodies and checkpoint inhibitors are approved for treatment of NSCLC. mAb’s successfully prevent formation of new blood vessels by tumor cells, thus facilitating inhibition of an alternative path for growth of tumor cells.